Skip to main content
SpringerLink
Log in

Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma

  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

A pilot phase I/II study was conducted as a single-institute trial for evaluation of the feasibility and efficacy of a new salvage chemotherapy, CHASE, for patients with refractory or relapsed lymphoma. The CHASE regimen, consisting of cyclophosphamide, cytosine arabinoside, etoposide, and dexamethasone, was administered every 3 weeks in a maximum of 5 courses. A total of 16 patients were eligible and registered for this study. Myelosuppression was the major toxicity. Although grade 4 leukopenia and grade 3 thrombocytopenia were identified in 15 and 16 patients, respectively, duration of the nadir was brief (median, 3 days). Nonhematological grade 4 toxicity was not observed, and transient elevations of bilirubin and grade 3 aspartate aminotransferase/alanine aminotransferase (AST/ALT) were observed in 2 and 3 courses, respectively, in a total of 57 courses. Complete and partial response rates were 71.4% (10/14) and 7.1% (1/14), respectively. The median percentage of maximal CD34+ cells was 6.1% on day 15, and a median number of 1.88 X 106 CD34+ cells/kg per apheresis were obtained. Thirteen patients received high-dose chemoradiotherapy followed by autologous peripheral blood stem cell transplantation. With a median follow-up time of 36 months from the start of CHASE, the overall survival rate for the 16 patients was 66.6%. These results indicated that CHASE is a safe and effective salvage regimen for malignant lymphoma, has sufficient mobilizing effect on peripheral blood stem cells, and warrants further phase II study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Devita VT Jr, Serpick AA, Carbone PP. Combination chemo- therapy in the treatment of advanced Hodgkin’s disease.Ann Intern Med. 1970;73:881–895.

    Article  PubMed  Google Scholar 

  2. Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin’s disease.J Clin Oncol. 1986;4:1295–1306.

    Article  PubMed  CAS  Google Scholar 

  3. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP.Cancer. 1975;36:252–259.

    Article  PubMed  CAS  Google Scholar 

  4. Bonadonna G, Valagussa P, Santoro A. Alternating non-cross- resistant combination chemotherapy or MOPP in stage IV Hodg- kin’s disease: a report of 8-year results.Ann Intern Med. 1986;104: 739–746.

    Article  PubMed  CAS  Google Scholar 

  5. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alter- nating with ABVD.N Engl J Med. 1992;327:1478–1484.

    Article  PubMed  CAS  Google Scholar 

  6. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma.Ann Intern Med. 1985;102:596–602.

    Article  PubMed  CAS  Google Scholar 

  7. Coiffier B, Bryon PA, Berger F, et al. Intensive and sequential com- bination chemotherapy for aggressive malignant lymphomas (pro- tocol LNH-80).J Clin Oncol. 1986;4:147–153.

    Article  PubMed  CAS  Google Scholar 

  8. Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of Pro- MACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trialJ Clin Oncol. 1991;9:25–38.

    Article  PubMed  CAS  Google Scholar 

  9. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma.N Engl J Med. 1993;328: 1002–1006.

    Article  PubMed  CAS  Google Scholar 

  10. Velasquez W, Fuller LM, Oh KK et al. Combined modality therapy in Stage III and Stage IIIE diffuse large cell lymphomas.Cancer. 1984;53:1478–1483.

    Article  PubMed  CAS  Google Scholar 

  11. DeVita VT Jr. Hodgkin’s disease: conference summary and future directions.Cancer Treat Rep. 1982;66:1045–1055.

    Google Scholar 

  12. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.N Engl J Med. 1984;311:1471–1475.

    Article  PubMed  CAS  Google Scholar 

  13. Anderson T, Bender RA, Fisher RI et al. Combination chemo- therapy in non-Hodgkin’s lymphoma: results of long-term fol- lowup.Cancer Treat Rep. 1977;61:1057–1066.

    PubMed  CAS  Google Scholar 

  14. Dana BW, Dahlberg S, Nathwani B, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.J Clin Oncol. 1993;11:644–651.

    Article  PubMed  CAS  Google Scholar 

  15. Lister TA. The management of follicular lymphoma.Ann Oncol. 1991;2(suppl 2):131–135.

    Article  PubMed  Google Scholar 

  16. Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma.J Clin Oncol. 1987;5:407–412.

    Article  PubMed  CAS  Google Scholar 

  17. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high- dose Ara-C and dexamethasone (DHAP).Blood. 1988;71:117–122.

    PubMed  CAS  Google Scholar 

  18. Dana BW, Dahlberg S, Miller TP, et al. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial.J Clin Oncol. 1990;8:1155–1162.

    Article  PubMed  CAS  Google Scholar 

  19. Weick JK, Dahlberg S, Fisher RI et al. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin’s lymphoma with MACOP-B: a Southwest Oncology Group study.J Clin Oncol. 1991;9:748–753.

    Article  PubMed  CAS  Google Scholar 

  20. Gams RA, Rainey M, Dandy M, Bartolucci AA., Silberman H, Omura G. Phase III study of BCOP v CHOP in unfavorable cate- gories of malignant lymphoma: a Southeastern Cancer Study Group trial.J Clin Oncol. 1985;3:1188–1195.

    Article  PubMed  CAS  Google Scholar 

  21. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone mar- row transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma.N Engl J Med. 1995;333:1540–1545.

    Article  PubMed  CAS  Google Scholar 

  22. Kasakura S. Recent developments in basic and clinical hemato- poietic stem cell transplantation [editorial].Int J Hematol. 2003; 77:1–2.

    Article  PubMed  Google Scholar 

  23. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow trans- plantation for B-cell lymphomaN Engl J Med. 1991;25:1525–1533.

    Article  Google Scholar 

  24. Freedman AS, Neuberg D, Mauch P, et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999;94:3325–3333.

    PubMed  CAS  Google Scholar 

  25. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autol- ogous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial.Lancet. 2002;359:2065–2071.

    Article  PubMed  CAS  Google Scholar 

  26. Kantarjian H, Barlogie B, Plunkett W, et al. High-dose cytosine ara- binoside in non-Hodgkin’s lymphoma.J Clin Oncol. 1983;1: 689–694.

    Article  PubMed  CAS  Google Scholar 

  27. Velasquez WS, McLaughlin P,Tucker S, et al. ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.J Clin Oncol. 1994;12:1169–1176.

    Article  PubMed  CAS  Google Scholar 

  28. Ohkubo T, Hori H, Higashigawa M, et al. Synergistic interaction between etoposide and 1-beta-D-arabinofuranosylcytosine.Adv Exp Med Biol. 1989;253B:355–362.

    Article  PubMed  CAS  Google Scholar 

  29. Chang TT, Gulati SC, Chou TC et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by com- puter analysis.Cancer Res. 1985;45:2434–2439.

    PubMed  CAS  Google Scholar 

  30. Ogura M, Kagami Y, Suzuki R, et al. Phase I/II trial of cure- oriented high-dose chemoradiotherapy with transplantation of CD34+ peripheral blood stem cells purified by the immunomag- netic bead method for refractory hematological malignancies. Nagoya CD34+ PBSCT Study Group.Cancer Chemother Pharma- col. 1997;40(suppl):S51-S57.

    Article  CAS  Google Scholar 

  31. Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.Jpn J Clin Oncol. 1993;23:250–257.

    Article  PubMed  CAS  Google Scholar 

  32. Adelstein DJ, Lazarus HM, Hines JD, Herzig RH. High-dose cyto- sine arabinoside in previously treated patients with poor-prognosis non-Hodgkin’s lymphoma.Cancer. 1985;56:1493–1496.

    Article  PubMed  CAS  Google Scholar 

  33. Freedman A, Gribben J, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.Blood. 1996;88:2780–2786.

    PubMed  CAS  Google Scholar 

  34. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemo- therapy.J Clin Oncol. 1999;17:268–276.

    Article  PubMed  CAS  Google Scholar 

  35. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxi- city and efficacy in relapsed and refractory non-Hodgkin’s lym- phoma.J Clin Oncol. 1993;11:1573–1582.

    Article  PubMed  CAS  Google Scholar 

  36. Olivieri A, Offidani M, Ciniero L, et al. DHAP regimen plus G-CSF as salvage therapy and priming for blood progenitor cell collection in patients with poor prognosis lymphoma.Bone Marrow Trans- plant. 1995;16:85–93.

    CAS  Google Scholar 

  37. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.Blood. 1994;83: 636–640.

    PubMed  CAS  Google Scholar 

  38. Freedman A, Neuberg D, Mauch P, et al. Cyclophosphamide, dox- orubicin, vincristine, prednisone dose intensification with granulo- cyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.Blood. 1997;90: 4996–5000.

    PubMed  CAS  Google Scholar 

  39. Voso MT, Pantel G, Weis M, et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin’s lym- phoma.Br J Haematol. 2000;109:729–735.

    Article  PubMed  CAS  Google Scholar 

  40. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.Blood. 2000;96:864–869.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Chemotherapy, Aichi Cancer Center Hospital, Kanokoden 1-1, Chikusaku, Nagoya, 464-8681, Aichi, Japan

    Michinori Ogura, Yoshitoyo Kagami, Hirofumi Taji, Ritsuro Suzuki, Kazuhisa Miura, Takahiro Takeuchi & Yasuo Morishima

Authors
  1. Michinori Ogura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitoyo Kagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hirofumi Taji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ritsuro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhisa Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takahiro Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasuo Morishima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michinori Ogura.

About this article

Cite this article

Ogura, M., Kagami, Y., Taji, H. et al. Pilot Phase I/II Study of New Salvage Therapy (CHASE) for Refractory or Relapsed Malignant Lymphoma. Int J Hematol 77, 503–511 (2003). https://doi.org/10.1007/BF02986620

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02986620

Key words

Search

Navigation